7 results
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
suspension 400 mg PO BID ... for effective treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating HHV-8 Diseases—Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL), Multicentric Castleman’s
recommended for KS treatment ... IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Managing Cryptosporidiosis in HIV-AIDS
Preventing Chronic Cryptosporidiosis:
 • Because chronic cryptosporidiosis occurs
should prevent the disease ... 500–1000 mg PO BID ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Treponema pallidum Infections (Syphilis) to Prevent Disease in HIV-AIDS
Early Stage (Primary, Secondary,
consultation to guide management ... IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Cytomegalovirus Infections in HIV-AIDS
Preventing CMV Disease:
 • CMV end-organ disease is best
Preventing CMV Disease ... Valganciclovir 900 mg PO BID ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Histoplasma Capsulatum Infections in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
Severe Disseminated Disease ... IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
Clarithromycin 500 mg PO BID ... IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology